AbbVie News Center - News
WEB1 day ago · AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs. September 06, 2024.
AbbVie to Acquire ImmunoGen, including its Flagship Cancer
WEBNov 30, 2023 · The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space. Additionally, ImmunoGen's follow-on pipeline of promising next-generation ADCs further complements AbbVie's ADC platform and existing programs.
AbbVie to Acquire Cerevel Therapeutics in Transformative ... - News
WEBDec 6, 2023 · Cerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipeline. Emraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditions. Transaction valued at $45.00 per share in cash, for a total equity value of approximately $8.7 billion.
AbbVie to Acquire Landos Biopharma, Further Strengthening its
WEBMar 25, 2024 · With AbbVie's therapeutic area leadership and expertise in global development, they are the right company to further advance NX-13." NLRX1 regulates immunometabolism and inflammation, and its activation impacts multiple mechanisms of inflammatory bowel disease (IBD) pathogenesis.
AbbVie Completes Acquisition of ImmunoGen - Feb 12, 2024
WEBFeb 12, 2024 · AbbVie expects its acquisition of ImmunoGen to be accretive to AbbVie's diluted EPS beginning in 2027 and significantly accretive over the long-term. Full-Year 2024 Outlook. AbbVie is reaffirming its previously issued 2024 full-year adjusted diluted EPS guidance range of $11.05-$11.25.
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
WEBFeb 2, 2024 · Reports Fourth-Quarter Diluted EPS of $0.46 on a GAAP Basis, a Decrease of 66.7 Percent; Adjusted Diluted EPS of $2.79, a Decrease of 22.5 Percent; These Results Include an Unfavorable Impact of $0.15 Per Share Related to Fourth-Quarter 2023 Acquired IPR&D and Milestones Expense.
AbbVie Announces Positive Topline Results from Phase 2 ... - News
WEBNORTH CHICAGO, Ill., Nov. 29, 2023 / PRNewswire / -- AbbVie (NYSE: ABBV) announced today topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell …
AbbVie Announces Appointment of Robert A. Michael as Chief …
WEBFeb 20, 2024 · Richard A. Gonzalez to retire as AbbVie CEO to become Executive Chairman. Transition will occur on July 1, 2024. NORTH CHICAGO, Ill., Feb. 20, 2024 / PRNewswire / -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously selected Robert A. Michael, AbbVie's current president and chief operating officer, to succeed ...
AbbVie Completes Transformative Acquisition of Allergan
WEBMay 8, 2020 · AbbVie Completes Transformative Acquisition of Allergan. - Creates biopharmaceutical company with leadership positions in key therapeutic areas: Immunology, Hematologic Oncology, Neuroscience, and Allergan Aesthetics. - Robust portfolio of on-market and pipeline assets well-positioned for sustainable long-term growth.
AbbVie Completes Acquisition of Cerevel Therapeutics
WEBAug 1, 2024 · AbbVie Completes Acquisition of Cerevel Therapeutics. Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's disease.
Skip to content